Intelligence

Behavioral Health Intelligence Dashboard

Regulation, markets, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health — monitored from public sources and reviewed with editorial judgment.

How this is built →

Regulatory Tracker

Recent public filings and regulatory signals from monitored government sources.

Regulatory tracker

0 filings today

Modulatory Effects of Personalized Transcranial Magnetic Stimulation (TMS) on Heart-Brain Coupling in Individuals With Depressive Tendencies

1d ago

Stress Ball Use in Non-Invasive Mechanical Ventilation Patients

1d ago

GUT-FEELINGS: Using Citizen Science for Large-Scale Prebiotic Clinical Trials for Mental Health in Adults

1d ago

Interpretation Bias Modification Training for Social Anxiety Disorder

1d ago

Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders

1d ago

Breathing Exercises for Dyspnea and Anxiety in Heart Failure

1d ago

Exploring Wellbeing Outcomes in Adolescents Using Bifidobacterium Longum, 1714™: a Prospective Open-Label Real-World Study

1d ago

The Effect of Standardized Withania Somnifera Extract on Endocrine, Metabolic, and Psychometric Parameters, in Women With Polyendocrine Metabolic Ovarian Syndrome

2d ago

See all filings →

Market Movers

Tracked equities connected to behavioral health: pharma psychiatry, psychedelics, cannabis, and digital health.

Movers

Gainers

Ticker	Last	%
CURLF	9.22	+10.42%
TDOC	7.13	+6.74%
TCNNF	9.00	+6.64%
HIMS	31.59	+6.51%

Losers

Ticker	Last	%
GHRS	30.27	-1.21%
LLY	1185.71	-0.52%
CMPS	13.54	-0.07%
DFTX	46.14	0.00%

Delayed quotes. Last updated 7 Aug 2026, 21:54 UTC.

View market coverage →

News Wire

Short signals from Behavioral Wire's coverage and monitored public sources.

News wire

POLICY

Puerto Rico opened a research-policy review on psychedelics and ibogaine, without authorizing any clinical use

PSYCHEDELICS

A Swiss real-world psilocybin cohort reported response and remission rates far below the field's early trials, closer to ordinary antidepressants

FDA

FDA approval adds Otsuka's SIMTRIYO (centanafadine) to the ADHD market, with launch pending DEA scheduling

MARKETS

Lilly agreed to acquire AtaiBeckley in a major psychedelic pipeline deal

POLICY

HHS and the VA signed a five-year MOU to prepare veterans' care for psychedelics

FDA

FDA issued final guidance on psychedelic trial design without loosening the bar

POLICY

Massachusetts's House passed a three-clinic psilocybin and ibogaine pilot, still needing the Senate and Governor

PSYCHEDELICS

A year-long naturalistic study mostly failed to find psychedelics' signature personality effect

Pipeline · Watchlist

Selected programs Behavioral Wire tracks across behavioral health markets.

Pipeline

Key programs currently tracked across behavioral health markets · scroll →

Last updated Jul 29, 2026

Approved

Zuranolone (Zurzuvae)

Postpartum depression

Marketed for PPD; MDD rejected

Updated Apr 18, 2026

Approved

AXS-05 (Auvelity)

Major depressive disorder

Marketed

Updated May 9, 2026

Approved

Esketamine (Spravato)

Treatment-resistant depression

Monotherapy label cleared

Updated Feb 27, 2026

Approved

Cobenfy (xanomeline-trospium)

Schizophrenia

ARISE adjunctive missed; Alzheimer's trials ongoing

Updated May 15, 2026

Approved

Centanafadine (SIMTRIYO)

ADHD (adults and children 6+, at least 20 kg)

FDA-approved July 2026 (first-in-class NDSRI); DEA scheduling pending before launch

Updated Jul 24, 2026

Phase 3

Navacaprant (NMRA-140)

Major depressive disorder

KOASTAL-2/-3 missed; development discontinued

Updated Jun 15, 2026

Phase 2

Emraclidine

Schizophrenia

Phase 2 failed; program written down

Updated Jan 22, 2026

Phase 3

COMP360 psilocybin

Treatment-resistant depression

Phase 3 complete; rolling NDA underway

Updated Jul 8, 2026

Phase 3

DT120 (lysergide ODT)

Major depressive disorder

Phase 3 positive; second trial enrolling

Updated Jun 23, 2026

Phase 3

DT120 (lysergide ODT)

Generalized anxiety disorder

Breakthrough designation

Updated May 2, 2026

Phase 3

MDMA-assisted therapy

PTSD

Pivotal trials complete; regulatory path unresolved

Updated Jun 6, 2025

Phase 3

HLP003 (deuterated psilocin)

Major depressive disorder

Breakthrough designation; Phase 3 APPROACH topline expected 2H 2026

Updated Jul 2, 2026

Phase 2

GH001 (inhaled mebufotenin)

Treatment-resistant depression

Phase 2 positive

Updated Mar 5, 2026

Phase 3

BPL-003 (intranasal mebufotenin)

Treatment-resistant depression

Phase 3 initiated; Lilly acquisition announced

Updated Jul 16, 2026

Phase 2

Luvesilocin (RE104)

Postpartum depression

Breakthrough designation; Phase 3 planned for 2026

Updated Feb 23, 2026

Phase 3

TSND-201 (methylone)

PTSD

Phase 3 underway; IMPACT-1 Phase 2 positive; acquired by Otsuka June 2026

Updated Jun 12, 2026

Approved

Epidiolex (cannabidiol)

Epilepsy; behavioral indications explored

Additional indications under study

Updated Feb 14, 2026

Phase 3

Zygel (CBD transdermal gel)

Fragile X syndrome

RECONNECT readout; FXS program phased out

Updated Feb 24, 2026

Approved

Rejoyn

Major depressive disorder (adjunct)

First FDA-cleared MDD app

Updated Apr 4, 2026

Phase 3

CT-155

Schizophrenia (negative symptoms)

CONVOKE Phase 3 positive; commercialization transferred to Click

Updated Apr 9, 2026

Approved

Sleepio / Daylight

Insomnia and anxiety

Marketed digital therapeutics

Updated Jan 12, 2026